Kymera Therapeutics, Inc. · NASDAQ:KYMR
Booth Bruce sold 398,765 Kymera Therapeutics, Inc. shares (Form 4)
Traded Jun 23 to Jun 25, 2026 · Filed Jun 25, 2026
From Jun 23 to Jun 25, 2026, Booth Bruce (Director) sold 398,765 Kymera Therapeutics, Inc. shares at an average US$110.31 for US$44M under a trading plan, leaving 564,668 shares. Filed Jun 25, 2026 (Form 4).
- Sold
- 398,765 shares
- Price
- US$110.31 average (US$99.98 to US$118.60)
- Value
- US$44M
- Holding after
- 564,668 shares (held indirectly)
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jun 23, 2026 | Common Stock | Sale | 1,235 | US$99.98 | 3,461,521 | Indirect |
| Jun 23, 2026 | Common Stock | Sale | 173 | US$99.98 | 613,589 | Indirect |
| Jun 24, 2026 | Common Stock | Sale | 103,688 | US$100.42 | 3,357,833 | Indirect |
| Jun 24, 2026 | Common Stock | Sale | 14,513 | US$100.42 | 599,076 | Indirect |
| Jun 24, 2026 | Common Stock | Sale | 14,490 | US$101.14 | 3,343,343 | Indirect |
| Jun 24, 2026 | Common Stock | Sale | 2,029 | US$101.14 | 597,047 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 9,994 | US$107.30 | 3,333,349 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 159 | US$108.02 | 3,333,190 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 14,351 | US$108.83 | 3,318,839 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 1,915 | US$110.30 | 3,316,924 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 614 | US$110.79 | 3,316,310 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 719 | US$111.89 | 3,315,591 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 10,215 | US$113.70 | 3,305,376 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 9,229 | US$114.65 | 3,296,147 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 58,205 | US$115.57 | 3,237,942 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 81,500 | US$116.53 | 3,156,442 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 24,268 | US$117.50 | 3,132,174 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 19,089 | US$118.60 | 3,113,085 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 1,399 | US$107.30 | 595,648 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 23 | US$108.02 | 595,625 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 2,011 | US$108.83 | 593,614 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 265 | US$110.30 | 593,349 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 86 | US$110.79 | 593,263 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 100 | US$111.89 | 593,163 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 1,437 | US$113.70 | 591,726 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 1,289 | US$114.65 | 590,437 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 8,389 | US$115.57 | 582,048 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 11,375 | US$116.53 | 570,673 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 3,359 | US$117.50 | 567,314 | Indirect |
| Jun 25, 2026 | Common Stock | Sale | 2,646 | US$118.60 | 564,668 | Indirect |
Source
Related
- Kymera Therapeutics, Inc.
- Booth Bruce
- Kymera Therapeutics, Inc. shareholders
- Form 4/A · Booth Bruce · Jul 2, 2026
- Form 4 · Booth Bruce · Jun 30, 2026
- Form 4 · Booth Bruce · Jun 30, 2026
- Form 4 · Booth Bruce · Jun 25, 2026
- Form 4 · Booth Bruce · Jun 22, 2026
- Form 4 · Mainolfi Nello · Oct 1, 2026
- Schedule 13G/A · T. Rowe Price Associates Inc · Sep 8, 2026
- Form 4 · Adams Brian · Sep 4, 2026
- Schedule 13G/A · T. Rowe Price Associates Inc · Aug 14, 2026
- Schedule 13G/A · Atlas Venture Fund X, L.P. · Aug 13, 2026